{"id":"https://openalex.org/W894231712","doi":"https://doi.org/10.1182/blood.v122.21.4062.4062","title":"Optimizing Dose Titration Of Ruxolitinib: The COMFORT-I Experience","display_name":"Optimizing Dose Titration Of Ruxolitinib: The COMFORT-I Experience","publication_year":2013,"publication_date":"2013-11-15","ids":{"openalex":"https://openalex.org/W894231712","doi":"https://doi.org/10.1182/blood.v122.21.4062.4062","mag":"894231712"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v122.21.4062.4062","doi":"https://doi.org/10.1182/blood.v122.21.4062.4062","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.4062.4062","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039057642","display_name":"Ruben A. Mesa","orcid":"https://orcid.org/0000-0001-5880-7972","observed_orcids":["https://orcid.org/0000-0001-5880-7972"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruben A. Mesa","raw_affiliation_strings":["Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ, USA,","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010075752","display_name":"Rami S. Komrokji","orcid":"https://orcid.org/0000-0002-1876-5269","observed_orcids":["https://orcid.org/0000-0002-1876-5269"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Rami S. Komrokji","raw_affiliation_strings":["Malignant Hematology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Malignant Hematology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA,","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089034990","display_name":"William Y. Sun","orcid":"https://orcid.org/0009-0007-2008-5055","observed_orcids":["https://orcid.org/0009-0007-2008-5055","https://orcid.org/0000-0003-3279-7408"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"William Sun","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE, USA,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112475383","display_name":"Victor A. Sandor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Victor A. Sandor","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE, USA,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5085521139","display_name":"Sr\u0111an Verstov\u0161ek","orcid":"https://orcid.org/0000-0002-6912-8569","observed_orcids":["https://orcid.org/0000-0002-6912-8569"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srdan Verstovsek","raw_affiliation_strings":["Department of Leukemia, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5010075752","https://openalex.org/A5089034990","https://openalex.org/A5112475383"],"corresponding_institution_ids":["https://openalex.org/I3019308854","https://openalex.org/I924451375"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.8659,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.74834812,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"122","issue":"21","first_page":"4062","last_page":"4062"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":1.0},{"id":"https://openalex.org/keywords/dose-titration","display_name":"dose titration","score":0.9399999976158142},{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.9860000014305115},{"id":"https://openalex.org/keywords/jak-inhibitors","display_name":"JAK inhibitors","score":0.6819999814033508},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.7229999899864197},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.9980000257492065},{"id":"https://openalex.org/keywords/platelet-count","display_name":"platelet count","score":0.8529999852180481},{"id":"https://openalex.org/keywords/baseline-hemoglobin","display_name":"baseline hemoglobin","score":0.8500000238418579},{"id":"https://openalex.org/keywords/red-blood-cell-transfusion","display_name":"red blood cell transfusion","score":0.8730000257492065},{"id":"https://openalex.org/keywords/risk-stratification","display_name":"risk stratification","score":0.45399999618530273},{"id":"https://openalex.org/keywords/hematological-adverse-events","display_name":"hematologic adverse events","score":0.4749999940395355}],"concepts":[{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.9024147391319275},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8010960817337036},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.7070634365081787},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6401774883270264},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.5240419507026672},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5218899846076965},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5055184364318848},{"id":"https://openalex.org/C2780240888","wikidata":"https://www.wikidata.org/wiki/Q6052586","display_name":"International Prognostic Scoring System","level":4,"score":0.44094574451446533},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.10065624117851257},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.08936512470245361},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v122.21.4062.4062","doi":"https://doi.org/10.1182/blood.v122.21.4062.4062","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.4062.4062","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2016406604","https://openalex.org/W1978004314","https://openalex.org/W2154558042","https://openalex.org/W2511028559","https://openalex.org/W7202366786","https://openalex.org/W2275402064","https://openalex.org/W4389218913","https://openalex.org/W2464767722","https://openalex.org/W2118152564","https://openalex.org/W2531614876"],"abstract_inverted_index":{"Abstract":[0,577,584,591],"Background":[1],"The":[2,82,198],"Janus-kinase":[3],"(JAK)":[4],"pathway":[5],"plays":[6],"a":[7,93,244,312,322,342,347,356,365,403,456,477,502],"critical":[8],"role":[9],"in":[10,34,107,112,133,146,187,423,506],"normal":[11],"hematopoiesis.":[12],"In":[13,142,497],"two":[14,308],"phase":[15],"3":[16],"studies,":[17],"the":[18,45,134,147,205,317,369,418,507,540],"JAK1/JAK2":[19],"inhibitor":[20],"ruxolitinib":[21],"(RUX)":[22],"demonstrated":[23],"clinical":[24],"benefit":[25,91,126,621],"over":[26,421],"placebo":[27],"(COMFORT-I)":[28],"or":[29,38,76,261,268,536,552,665],"best":[30],"available":[31],"therapy":[32,256,283,533],"(COMFORT-II)":[33],"patients":[35,72,86,108,122,148,159,363,382,424,434,469,489,500,525,543,619],"with":[36,51,160,174,218,321,383,394,518],"intermediate-2":[37],"high-risk":[39],"myelofibrosis":[40],"(MF).":[41],"Anemia":[42],"and":[43,56,69,130,168,204,229,291,331,341,355,390,440,513,566,602,631],"thrombocytopenia,":[44],"most":[46,89,206,499,524],"common":[47,207],"adverse":[48],"events":[49,65],"associated":[50],"RUX":[52,111,151,245,375,405,503,546,630],"treatment,":[53],"were":[54,66,152,182,213,235,303,516],"dose-dependent":[55],"expected":[57],"based":[58],"on":[59,427,659],"RUX's":[60],"mechanism":[61],"of":[62,139,164,201,247,254,264,276,282,316,345,362,373,381,387,392,461,481,511,542,548,597,606,629,663],"action.":[63],"These":[64],"successfully":[67],"managed":[68],"few":[70],"RUX-treated":[71],"discontinued":[73],"for":[74,79,158,172,184,196,271,306,433,444,616],"anemia":[75,267,493],"thrombocytopenia":[77],"(<1%":[78],"each":[80],"event).":[81,286],"ability":[83],"to":[84,98,114,150,237,243,310,402,408,526,545,560],"identify":[85,115],"who":[87,109,123,425],"would":[88,124,470,490],"likely":[90],"from":[92,127,622],"dose":[94,131,194,202,212,246,258,366,406,420,504,633],"adjustment":[95,367,505],"may":[96,466,486,611,620],"contribute":[97],"improved":[99],"patient":[100,116],"management.":[101],"Therefore,":[102],"an":[103,351,472,492,660],"analysis":[104],"was":[105,191,429],"conducted":[106,236,305],"received":[110],"COMFORT-I":[113],"characteristics":[117,300],"that":[118,455],"could":[119],"help":[120],"select":[121],"potentially":[125],"closer":[128,623],"monitoring":[129,624],"titration":[132,242,259,474,522],"early":[135,473],"period":[136],"after":[137,626],"initiation":[138,284,628],"therapy.":[140,520],"Methods":[141],"COMFORT-I,":[143,498],"starting":[144,211,255,410,435,446,532],"doses":[145,209,515,547],"randomized":[149],"15":[153,437,535],"mg":[154,170,249,431,438,442,449,538,550],"twice":[155],"daily":[156],"(BID)":[157],"baseline":[161,219,288,384,395,457,478,594,603],"platelet":[162,175,188,223,289,385,396,458,529,595],"counts":[163,176,386,397],"100\u2013200":[165,388],"\u00d7109/L":[166,178,389,399,601],"(n=55)":[167],"20":[169,448,537],"BID":[171,250,432,439,443,450,551],"those":[173,393,445],">200":[177,398],"(n=100).":[179],"Dose":[180,521],"reductions":[181,565],"required":[183],"protocol-defined":[185],"decreases":[186],"counts;":[189],"there":[190],"no":[192],"protocol-mandated":[193],"change":[195],"anemia.":[197],"time":[199,422],"course":[200],"adjustments":[203,634],"titrated":[208,401,544],"by":[210],"evaluated.":[214],"Logistic":[215],"regression":[216],"analyses":[217,302,453],"hemoglobin":[220],"(Hgb)":[221],"level,":[222],"count,":[224],"IPSS":[225],"risk":[226],"category,":[227],"sex,":[228],"MF":[230],"type":[231],"as":[232,294,635],"model":[233],"effects":[234],"determine":[238,311],"predictors":[239,296,309],"of:":[240],"1)":[241],"\u226410":[248],"within":[251,279,368],"8":[252],"weeks":[253,281,372,510],"(early":[257],"event);":[260],"2)":[262],"development":[263],"grade":[265],"\u22653":[266],"new":[269],"need":[270],"RBC":[272],"transfusions":[273],"(\u22652":[274],"units":[275],"packed":[277],"RBCs)":[278],"12":[280,371,509],"(anemia":[285],"Only":[287],"count":[290,459,596],"Hgb":[292,479,604],"emerged":[293],"significant":[295],"(alpha=0.05).":[297],"Receiver":[298],"operating":[299],"(ROC)":[301],"also":[304],"these":[307],"clinically":[313,613],"relevant":[314],"cutoff":[315],"underlying":[318],"predictor":[319],"variable":[320],"positive":[323,328,333],"predictive":[324],"value":[325],"(PPV),":[326],"true":[327],"rate":[329,334],"(TPR),":[330],"false":[332],"(FPR)":[335],"obtained":[336],"at":[337,436,447,534],"all":[338],"possible":[339],"cutoffs":[340,615],"general":[343],"goal":[344],"obtaining":[346],"TPR":[348],"\u2265":[349],"50%,":[350],"FPR":[352],"\u2264":[353],"10%,":[354],"high":[357],"PPV.":[358],"Results":[359],"Approximately":[360],"70%":[361],"had":[364,400],"first":[370,508],"initiating":[374],"treatment.":[376],"At":[377],"week":[378],"24,":[379],"77%":[380],"39%":[391],"reduced":[404],"relative":[407],"their":[409],"dose.":[411],"With":[412],"longer-term":[413],"follow-up":[414],"(median":[415],"149":[416],"weeks),":[417],"mean":[419],"continued":[426],"study":[428],"\u223c10":[430],"\u223c15":[441],"(Figure).":[451],"ROC":[452],"identified":[454],"range":[460],"less":[462,482,598,607],"than":[463,483,599,608],"150\u2013175":[464],"x109/L":[465],"predict":[467,487],"which":[468,488,554,618],"experience":[471,491],"event,":[475],"while":[476],"level":[480,605],"10":[484,549,609],"mg/dL":[485],"event":[494],"(Table).":[495],"Conclusions":[496],"experienced":[501],"treatment":[512,627],"stable":[514],"achieved":[517],"long-term":[519],"allowed":[523],"maintain":[527],"adequate":[528],"counts.":[530],"After":[531],"BID,":[539],"majority":[541],"higher,":[553],"have":[555],"been":[556,558],"previously":[557],"shown":[559],"produce":[561],"meaningful":[562],"spleen":[563],"volume":[564],"symptom":[567],"improvements":[568],"(Mesa":[569],"et":[570,580,587],"al.":[571,581,588],"8th":[572],"Annual":[573],"Hematologic":[574],"Malignancies":[575],"Conference.":[576],"305;":[578],"Verstovsek":[579],"ASH":[582,589],"2012.":[583,590],"800;":[585],"Talpaz":[586],"176).":[592],"A":[593],"150":[600],"g/dL":[610],"be":[612],"useful":[614],"predicting":[617],"shortly":[625],"appropriate":[632],"needed.":[636],"Disclosures:":[637],"Mesa:":[638],"Lilly:":[639],"Research":[640,643,647,650,654,684],"Funding;":[641,644,648,651],"Genentech:":[642],"NS":[645],"Pharma:":[646],"Gilead:":[649],"Incyte":[652,672,679],"Corporation:":[653,657,669,673,676,680,683],"Funding.":[655,685],"Komrokji:Incyte":[656],"Membership":[658],"entity\u2019s":[661],"Board":[662],"Directors":[664],"advisory":[666],"committees.":[667],"Sun:Incyte":[668],"Equity":[670,677],"Ownership;":[671,678],"Employment.":[674,681],"Sandor:Incyte":[675],"Verstovsek:Incyte":[682]},"counts_by_year":[{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}